RespireRx Pharmaceuticals Inc (RSPI)

[NeutrinoKid]

More press.

Mild Cognitive Impairment Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | FUJIFILM Toyama Chemical Co. Ltd., Aptinyx, AgeneBio, Eisai Inc., RespireRx, Allon Therapeutics, CuraSen Therapeutics
05-02-2024 08:01 PM CET | Health & Medicine
Press release from: DelveInsight Business Research

“• Key Mild Cognitive Impairment Companies: FUJIFILM Toyama Chemical Co. Ltd., Aptinyx, AgeneBio, Eisai Inc., RespireRx, Allon Therapeutics, CuraSen Therapeutics, Inc., Avraham Pharma, AstraZeneca, Sage Therapeutics, Pfizer, Materia Medica Holding, Eli Lilly and Company, GE Healthcare, Parexel, and others
• Key Mild Cognitive Impairment Therapies: T-817MA, NYX-458, Aptinyx, T-817MA, Aricept (donepezil hydrochloride), CX516, AL-208, CST-2032, ladostigil hemitartrate, AZD5213, SAGE-718, fesoterodine, MMH-MAP, Donanemab, Flutemetamol (18F) Injection, EVP-0962, and others “

“Mild Cognitive Impairment Therapies and Key Companies
• T-817MA: FUJIFILM Toyama Chemical Co. Ltd.
• NYX-458: Aptinyx
• Aptinyx: AgeneBio
• T-817MA: FUJIFILM Toyama Chemical Co., Ltd.
• Aricept (donepezil hydrochloride): Eisai Inc.
• CX516: RespireRx
• AL-208: Allon Therapeutics
• CST-2032: CuraSen Therapeutics, Inc.
• ladostigil hemitartrate: Avraham Pharma
• AZD5213: AstraZeneca
• SAGE-718: Sage Therapeutics
• fesoterodine: Pfizer
• MMH-MAP: Materia Medica Holding
• Donanemab: Eli Lilly and Company
• Flutemetamol (18F) Injection: GE Healthcare
• EVP-0962: Parexel“

https://www.openpr.com/news/3483246/mild-cognitive-impairment-market-to-observe-impressive-growth